Market Overview

UPDATE: Deutsche Bank Reiterates on Alexion Pharmaceuticals Ahead of Asfotase Alfa Launch

Related ALXN
Raptor Announces CEO Succession Plan; Dr. Christopher Starr To Retire As CEO At Year-End 2014, Julie Anne Smith Named President And CEO-Designate
Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

In a report published Monday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and raised the price target from $125.00 to $205.00.

In the report, Deutsche Bank noted, “The next new product launch for Alexion is Asfotase Alfa for severe Hypophosphatasia (HPP). Our deep dive into the drug suggests the market is bigger vs. street expectations. We also updated our Soliris & expense assumptions to more accurately reflect company guidance. We believe incidence is greater than literature suggests & model 1/25,000 in US & 1/50,000 ex-US of severe pediatric HPP.”

Alexion Pharmaceuticals closed on Friday at $163.63.

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (ALXN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free

Benzinga Professional